Andrea Necchi, Associate Editor at Journal of Clinical Oncology, shared a post on LinkedIn:
“Adding Systemic immunotherapy to standard intravesical BCG is controversial. Data from Phase 3 trial are still not conclusive although two of them are positive.
Therapeutic attrition, perceived missed opportunities for sequential therapies, side effects and the magnitude of benefit (reconstructed KM curves by Brigida Anna Maiorano) count in decision-making.”
Title: Bacillus Calmette-Guérin (BCG) and Beyond: Is Systemic Immunotherapy for BCG-Naïve Non-Muscle-Invasive Bladder Cancer Progress or Overreach?
Authors: Ashish M. Kamat, Patrick J. Hensley, Brigida A. Maiorano, Roger Li, Sarah P. Psutka, Kent W. Mouw, Amir Horowitz, Shilpa Gupta, Andrea Necchi
Read the full article here.
Other articles featuring Andrea Necchi on OncoDaily.